These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 18501490

  • 21. [Significance of mutagenicity tests on safety evaluation of medicinal drugs].
    Sofuni T.
    Eisei Shikenjo Hokoku; 1993; (111):149-50. PubMed ID: 7920563
    [Abstract] [Full Text] [Related]

  • 22. Single dose toxicity and repeated dose toxicity studies: introductory remarks.
    Kurokawa Y, Matsuzawa T.
    J Toxicol Sci; 1996 Dec; 21(5):413-6. PubMed ID: 9035047
    [No Abstract] [Full Text] [Related]

  • 23. Final amended report on the safety assessment of oxyquinoline and oxyquinoline sulfate as used in cosmetics.
    Andersen A.
    Int J Toxicol; 2006 Dec; 25 Suppl 1():1-9. PubMed ID: 16835127
    [Abstract] [Full Text] [Related]

  • 24. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L, Rouan MC, Raoof A, Bailey GP, De Zwart L, Monbaliu J, Coogan TP, Lammens L, Coussement W.
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [Abstract] [Full Text] [Related]

  • 25. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
    Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, Lampo A, Nahas K, Nogues V, Ockert D, Quinn K, Old S, Pickersgill N, Somers K, Stark C, Stei P, Waterson L, Chapman K.
    Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
    [Abstract] [Full Text] [Related]

  • 26. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL, Baker TK.
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [Abstract] [Full Text] [Related]

  • 27. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY, Milton M, Lloyd P, Sims J, Brennan FR.
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [Abstract] [Full Text] [Related]

  • 28. Preclinical safety evaluation of recombinant human interleukin-10.
    Rosenblum IY, Johnson RC, Schmahai TJ.
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
    [Abstract] [Full Text] [Related]

  • 29. [Toxicological assessment on safety of water and 70% ethanolic extracts of nearly ripe fruit of Evodia rutaecarpa].
    Yang XW.
    Zhongguo Zhong Yao Za Zhi; 2008 Jun; 33(11):1317-21. PubMed ID: 18831217
    [Abstract] [Full Text] [Related]

  • 30. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK.
    Toxicol Lett; 2009 Nov 12; 190(3):239-42. PubMed ID: 19695319
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S, Hamon J, Bojanic D, Urban L.
    Drug Discov Today; 2005 Nov 01; 10(21):1421-33. PubMed ID: 16243262
    [Abstract] [Full Text] [Related]

  • 34. The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program.
    Herlich JA, Taggart P, Proctor J, Stahle P, Colis R, Hall L, Pugsley MK.
    Proc West Pharmacol Soc; 2009 Nov 01; 52():94-8. PubMed ID: 22128433
    [Abstract] [Full Text] [Related]

  • 35. A sub-chronic (13 weeks) oral toxicity study in rats and an in vitro genotoxicity study with Korean pine nut oil (PinnoThin TG).
    Speijers GJ, Dederen LH, Keizer H.
    Regul Toxicol Pharmacol; 2009 Nov 01; 55(2):158-65. PubMed ID: 19559745
    [Abstract] [Full Text] [Related]

  • 36. Pre- and postnatal developmental toxicity study design for pharmaceuticals.
    Bailey GP, Wise LD, Buschmann J, Hurtt M, Fisher JE.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec 01; 86(6):437-45. PubMed ID: 20025040
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Review of L-tyrosine confirming its safe human use as an adjuvant.
    Baldrick P, Richardson D, Wheeler AW.
    J Appl Toxicol; 2002 Dec 01; 22(5):333-44. PubMed ID: 12355563
    [Abstract] [Full Text] [Related]

  • 39. Embryo-fetal developmental toxicity study design for pharmaceuticals.
    Wise LD, Buschmann J, Feuston MH, Fisher JE, Hew KW, Hoberman AM, Lerman SA, Ooshima Y, Stump DG.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec 01; 86(6):418-28. PubMed ID: 20025038
    [Abstract] [Full Text] [Related]

  • 40. Regulatory forum opinion piece: obligatory microscopic examination of intermediate dose groups in non-rodent toxicity studies--is it necessary?
    Weddle DL, Mahrt CR, Schmidt SP.
    Toxicol Pathol; 2012 Jul 01; 40(5):826-9. PubMed ID: 22421750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.